Chicago Trust Co Na Lowers stake in Amgen (AMGN)

Amgen (AMGN) : Chicago Trust Co Na reduced its stake in Amgen by 1.68% during the most recent quarter end. The investment management company now holds a total of 16,338 shares of Amgen which is valued at $2,684,660 after selling 279 shares in Amgen , the firm said in a disclosure report filed with the SEC on Oct 12, 2016.Amgen makes up approximately 1.24% of Chicago Trust Co Na’s portfolio.

Other Hedge Funds, Including , Vista Capital Partners boosted its stake in AMGN in the latest quarter, The investment management firm added 121 additional shares and now holds a total of 1,680 shares of Amgen which is valued at $276,058. Amgen makes up approx 0.03% of Vista Capital Partners’s portfolio.Carroll Financial Associates boosted its stake in AMGN in the latest quarter, The investment management firm added 53 additional shares and now holds a total of 5,426 shares of Amgen which is valued at $913,250. Amgen makes up approx 0.14% of Carroll Financial Associates’s portfolio.Pacwest Financial Management Inc reduced its stake in AMGN by selling 157 shares or 1.37% in the most recent quarter. The Hedge Fund company now holds 11,308 shares of AMGN which is valued at $1,903,249. Amgen makes up approx 1.17% of Pacwest Financial Management Inc’s portfolio.Reilly Herbert Faulkner Iii boosted its stake in AMGN in the latest quarter, The investment management firm added 580 additional shares and now holds a total of 26,933 shares of Amgen which is valued at $4,533,093. Amgen makes up approx 3.41% of Reilly Herbert Faulkner Iii’s portfolio.First United Bank Trust boosted its stake in AMGN in the latest quarter, The investment management firm added 285 additional shares and now holds a total of 6,486 shares of Amgen which is valued at $1,091,659. Amgen makes up approx 0.91% of First United Bank Trust’s portfolio.

Amgen closed down -3.99 points or -2.37% at $164.32 with 27,61,896 shares getting traded on Tuesday. Post opening the session at $167.82, the shares hit an intraday low of $163.51 and an intraday high of $167.82 and the price fluctuated in this range throughout the day.Shares ended Tuesday session in Red.

On the company’s financial health, Amgen reported $2.84 EPS for the quarter, beating the analyst consensus estimate by $ 0.10 according to the earnings call on Jul 27, 2016. Analyst had a consensus of $2.74. The company had revenue of $5688.00 million for the quarter, compared to analysts expectations of $5579.33 million. The company’s revenue was up 5.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.57 EPS.

Amgen Inc. (Amgen) is a biotechnology company. The Company is engaged in discovering developing manufacturing and delivering human therapeutics. The Company’s sales and marketing forces are located in the United States and Europe. In the United States it sells its products to pharmaceutical wholesale distributors. The Company also markets certain products directly to consumers through direct-to-consumer print and television advertising as well as through the Internet. Outside the United States the Company sells its products to healthcare providers and/or pharmaceutical wholesale distributors. The Company’s products include Neulasta (pegfilgrastim)/NEUPOGEN (filgrastim) Enbrel (etanercept) XGEVA/Prolia (denosumab) ESAs (erythropoiesis-stimulating agents) Sensipar/Mimpara (cinacalcet) Kyprolis and Evolocumab among others.

Leave a Reply

Amgen - Is it time to Sell?

Top Brokerage Firms are advising their investors on Amgen. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.